Associate Professor of Neurological Surgery, University Tex Houston
Neurosurgery
Dr. Amy B. Heimberger, MD
|
|
Give Review
Doctor Amy B. Heimberger, MD is an expert in the field of Neurosurgery. She went to Washington University School of Medicine in St. Louis. She received awards:"Top Doctors:SE Texas", "Elected Member" and "Fellow (FAANS)". Heimberger has written publications. She has 80 publications published with PubMed. The lastest paper is: 'Compartmentalization of catalases in Escherichia coli.' Heimberger accepts Medicare payments and is listed with Medicare.gov.
Publications
- PD-L1 expression and prognostic impact in glioblastoma.
- Immunosuppressive mechanisms in glioblastoma.
- The role of STAT3 in tumor-mediated immune suppression.
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
- Immunotherapy for primary Brain tumors: no longer a matter of privilege.
- Therapeutic targets in subependymoma.
- Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis.
- The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.
- Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma.
- MicroRNAs as novel immunotherapeutics.
- miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma.
- A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal Brain tumors.
- BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
- Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma.
- The Expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival.
- miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma.
- The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.
- Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas.
- Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
- Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
- Hypoxia potentiates glioma-mediated immunosuppression.
- Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.
- Glioma Cancer stem cells induce immunosuppressive macrophages/microglia.
- Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed gli...
- Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.
- Glioma-associated Cancer-initiating cells induce immunosuppression.
- Clinical applications of a peptide-based vaccine for glioblastoma.
- The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
- Glioblastoma Cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.
- An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
- Awake craniotomy for Brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients.
- The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.
- Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.
- The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human Gliomas.
- A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central Nervous system melanoma and inhibits re...
- Incidence and prognostic impact of FoxP3+ regulatory T cells in human Gliomas.
- Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
- Altered adenosine-to-inosine RNA editing in human Cancer.
- A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.
- Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.
- Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
- The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.
- Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.
- Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
- Loss of the AP-2alpha transcription factor is associated with the grade of human Gliomas.
- Mechanisms of action of rapamycin in Gliomas.
- Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
- Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
- Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.
- The controversial role of microglia in malignant Gliomas.
- Immune therapeutic targeting of glioma Cancer stem cells.
- The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central Nervous system malignancies.
- EGFRvIII-targeted vaccination therapy of malignant glioma.
- The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
- yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients.
- A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.
- Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS Cancers.
- Innate immune functions of microglia isolated from human glioma patients.
- The natural history of EGFR and EGFRvIII in glioblastoma patients.
- Immunotherapy for human glioma: innovative approaches and recent results.
- Central Nervous system cancers: Clinical Practice Guidelines in Oncology.
- Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
- Topotecan enhances immune clearance of Gliomas.
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
- Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant Gliomas in rats.
- Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma.
- Compartmentalization of catalases in Escherichia coli.
- Catalase HPI influences membrane permeability in Escherichia coli following near-UV stress.
- Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo.
- Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic System.
- Biphasic malignant meningioma: a comparative genomic hybridization study.
- Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
- A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo.
- Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
- IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
- Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
- Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.
- Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.
Schools
Washington University St Louis
Duke University Med Center
University Of Missouri
Procedures Preformed
- Cerebrospinal Fluid (CSF) Shunt - Insertion, Repair or Removal
- Craniectomy, Craniotomy, Surgery of Skull Base, Neuroendoscopy
- Nerve Block, Somatic
- Spinal Nerve Block
- View All
Conditions Treated
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Aneurysm
- Brain Cancer
- Brain Injury
- View All
Doctors Specialties
- Neurosurgery
Accepted Insurances
Awards
- Top Doctors:SE Texas
- Elected Member
- Fellow (FAANS)
Education
-
Duke University Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
University of Texas M.D. Anderson Cancer Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235220955 |
| Last Name Of The Provider | HEIMBERGER |
| First Name Of The Provider | AMY |
| View All |
Similar Doctors
|
|
Dr. Thomas J. Mims, MD |
|
Dr. Peter J. Yeh, MD |
|
Dr. Scott R. Shepard, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karl M. Schmitt Jr., MD |
|
|
Dr. Martin Blacker, MD |
|
|
Dr. Richard M. Hirshberg, MD |
|
|
Dr. Elbert F. Robinson, MD |
|
|
Dr. Mark J. Dannenbaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shane Abdunnur, MD
This Doctor is OpenDoctor Recommended.
|